XBiotech Inc. is a fully integrated biosciences company focused on the discovery and development of therapeutic antibodies derived from natural human immunity. The company develops True Human monoclonal antibodies, which are distinct from humanized or engineered antibodies, to address critical unmet medical needs in inflammatory and infectious diseases. Its pipeline targets therapeutic areas including oncology, neurology, rheumatology, and anti-infectives, with specific candidates for conditions such as cancer, diabetes, pyoderma gangrenosum, and Staphylococcus aureus infections. XBiotech maintains R&D and manufacturing operations in Austin, Texas, and has previously maintained research facilities in Copenhagen and Zurich. The company has engaged in clinical trials with partners such as MD Anderson Cancer Center and has a history of licensing assets, including the acquisition of its candidate bermekimab by Janssen. Founded in 2005, XBiotech operates its own manufacturing infrastructure to produce its antibody candidates for clinical and commercial use.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage xbiotech.com
Sector Healthcare IR page investors.xbiotech.com
Tags
monoclonal antibodies, oncology, rheumatology, anti-infectives, neurology, inflammatory diseases, natural human immunity, therapeutic antibodies, clinical trials, biosciences, True Human, bermekimab, XBiotech USA, Janssen, MD Anderson
Press page xbiotech.com/news

Metrics

Valuation  
Market cap $ 62.46M
Market cap (USD) $ 62.46M
P/E -1.44
PEG —
P/BV 0.50
P/S 15.58
P/OCF -1.53
P/FCF -1.52
Dividend yield —
Turnover / mcap —
Returns  
ROE -28.2%
ROI -32.4%
ROIC -29.8%
Profit margin —
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 12
Quality score -46.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue — — 0 4.01M 18.394M 43.997M — — — — — —
Net profit -45.54M -38.531M -24.557M -32.9M -17.414M -11.221M 668.629M -21.138M -33.15M -50.722M -37.483M -21.724M
Free cash flow -40.209M -32.267M -19.087M -15.409M 65.92M -68.876M -18.474M -16.659M -35.054M -50.761M -35.63M -13.097M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 2.39 3.95 4 3.51 11.13 15.65 18.67 5.08 3.93 10.12 10.87 —
Price performance 12m -0.39 -0.01 0.14 -0.68 -0.29 -0.16 2.67 0.29 -0.61 -0.07 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — 0.00 4.11M 0.00 1.22M 860,000 700,000 —
↳ YoY growth -100.0% -29.3% -18.6%
Cash and deposits (USD) 34.3M 31.8M 15.8M 715M 237M 237M 157M 200M 173M 126M
Cash flow detail
Operating cash flow (USD) -46M -33.6M -16.5M -18.3M -65.1M 69.4M -14.8M -18.7M -31M -39.9M
Purchases of property, plant and equipment (USD) -4.75M -1.41M -122,000 -204,000 -3.73M -3.53M -585,000 -362,000 -1.3M -289,000
Change in receivables (cash effect) (USD) — — 0.00 0.00 -4.11M 4.11M 0.00 — — —
Change in payables (cash effect) (USD) -981,000 -2.7M -78,000 496,000 -334,000 -514,000 357,000 91,000 -364,000 -688,000
Dividends paid (cash effect) (USD) — — — 0.00 0.00 -75M 0.00 — — —
Share buybacks (cash effect) (USD) — — — — — — 0.00 -14,000 0.00 —
Interest paid (cash effect) (USD) — — — — — — — 0.00 -400,000 -486,000
Income taxes paid (cash effect) (USD) — — 0.00 0.00 -54.1M 0.00 — -141,000 -85,000 81,000
Share-based compensation (USD) 5.57M 1.75M 1.66M 3.36M 12.6M 4.46M 5.06M 3.26M 1.75M 3.62M
Operating cash flow before change in receivables (USD) — — -16.5M -18.3M -61M 65.3M -14.8M — — —
Free cash flow (OCF - PPE - intangibles) (USD) -50.8M -35.1M -16.7M -18.5M -68.9M 65.9M -15.4M -19.1M -32.3M -40.2M
Income detail
Research and development expense (USD) 42.5M 26.4M 15.7M 24.1M 9.53M 28.3M 31.5M 32.8M 37.8M 47.4M
↳ 5y CAGR +14.7% +10.9% -21.2% -7.8% +3.6% +15.9% +9.4% +37.8%
Total comprehensive income (USD) -52.5M -34M -20.6M 669M -9.85M -16.7M -34M -25.4M -38.5M —
Comprehensive income to owners (USD) -52.5M -34M -20.6M 669M -9.85M -16.7M -34M -25.4M -38.5M —
Reported Mar 16, 2017 Mar 16, 2018 Mar 16, 2021 Mar 15, 2022 Mar 15, 2022 Mar 15, 2022 Mar 15, 2024 Mar 18, 2025 May 14, 2025 Mar 13, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Oct 23, 2026

PDF Version

AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026.

“On behalf of the Board of Directors, we are excited to announce Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers,” said Director Tevi Troy. “Their complementary skill sets, scientific acumen, and shared commitment to our mission position XBiotech to fully realize the potential of our True-Human antibody therapies.”

Dr. Shivaswamy has been with XBiotech for 17 years, having served as Senior Scientist, Director and Vice President of Research & Development prior to her appointment as Chief Scientific Officer in 2017. As CSO, Dr. Shivaswamy oversaw scientific and technical operations spanning R&D through GMP production of antibodies. In December of 2025, Dr. Shivaswamy was named interim CEO following the retirement of Founder John Simard.

“As our industry evolves, so must our approach to leadership,” said Dr. Shivaswamy. “Appointing Jan-Paul Simard as Co-CEO reflects our commitment to staying proactive, adaptive, and relentlessly focused on execution. He brings a distinct perspective and operational continuity that strengthens our decision-making. I look forward to working side-by-side to deliver lasting value to our patients and shareholders”.

Jan-Paul Simard started at XBiotech in 2012 as an R&D assistant before transitioning in 2020 to the clinical development team, where he contributed to study design and protocol development across clinical trials in pancreatic cancer, non-small cell lung cancer, osteoarthritis, and rheumatoid arthritis. He has continued his scientific education in Chemistry with Honours at the University of Saskatchewan, further strengthening his expertise in clinical and biological sciences.

“It is an honour to step into this leadership role at such a pivotal moment for XBiotech, especially in tandem with a scientist as accomplished as Dr. Shivaswamy,” said Mr. Simard. “Her leadership as interim CEO has positioned the company to capitalize on its pipeline of drug candidates, and I look forward to partnering with her and our talented team to advance new therapies.”

About XBiotechXBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ discovery platform. XBiotech currently is advancing antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking StatementsThis press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Oct 19, 2026

PDF Version

Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival.

Exploratory Subgroup analysis reveals significant survival benefit in right-sided tumors.

AUSTIN, Texas, Oct. 19, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced positive final efficacy results from the randomized Phase II portion of the multicenter TASKIN clinical trial. The investigator-sponsored study—funded by the French National Cancer Institute (INCa) and coordinated by investigators at the Centre Georges-François Leclerc (CGFL) in Dijon, France—evaluated the addition of XBiotech’s anti-IL-1α monoclonal antibody, XB2001 (Natrunix™, vilamakitug), to standard-of-care trifluridine/tipiracil (TAS-102) with or without bevacizumab in patients with refractory metastatic colorectal cancer (mCRC).

The TASKIN Phase II study met its pre-specified primary efficacy success criterion under a Simon two-stage design. At the 12-month landmark analysis, 49 of 80 evaluable patients (61.3%) in the vilamakitug experimental arm were alive, surpassing the protocol-defined threshold of 42 or more surviving patients required to establish efficacy. In the control arm (placebo plus standard chemotherapy), 44 of 79 evaluable patients (55.7%) were alive at 12 months.

Professor François Ghiringhelli, M.D., Ph.D., Principal Investigator of the TASKIN study and Director of the Oncology Department at Centre Georges-François Leclerc, commented:

"Patients with refractory metastatic colorectal cancer face severe therapeutic limitations and poor survival outcomes. Meeting our pre-specified primary milestone provides compelling evidence that targeting IL-1α plays a meaningful role in tumor biology. Most striking is the magnitude of benefit observed in right-sided colorectal cancers, which has been a historically aggressive disease subset with high unmet medical need. The alignment between this pronounced clinical survival advantage and elevated basal IL-1α tumor expression offers a clear biological rationale for this therapy."

Summary of Overall Findings

  • Time to Strategy Failure (TSF): The 12-month TSF rate, which captured the duration for which the overall treatment strategy remains viable, was 31.2% in the vilamakitug arm compared to 20.3% in the control arm (log-rank p = 0.17).

  • Progression-Free Survival (PFS): Median PFS was 5.9 months for the vilamakitug arm versus 5.6 months for the control arm, with a 12-month PFS rate of 25.0% versus 21.0% (log-rank p = 0.42), with survival curves visibly separating after month 7.

  • Safety & Treatment Adherence: Vilamakitug demonstrated high feasibility in combination with chemotherapy, showing a 96.4% mean compliance rate for trifluridine/tipiracil and only a 1.3% permanent discontinuation rate for vilamakitug/placebo

Exploratory Endpoint Analysis, Efficacy in Right-Sided Primary Tumors

A prospective exploratory analysis identified a statistically significant benefit in patients with right-sided (proximal) primary tumors (n = 37), a subtype characterized by aggressive tumor biology, high unmet medical need, and poor outcomes under standard therapies:

  • Overall Survival (OS): Vilamakitug demonstrated a statistically significant 62% reduction in the risk of death compared to control (Hazard Ratio [HR] = 0.38; 95% CI: 0.14–0.99; Cox p = 0.047, log-rank p = 0.038) through 12 months.

  • Time to Strategy Failure (TSF): Vilamakitug achieved a 61% reduction in the risk of treatment strategy failure compared to control (HR = 0.39; 95% CI: 0.18–0.85; Cox p = 0.017, log-rank p = 0.014) through 12 months.

Sushma Shivaswamy, Ph.D., Chief Scientific Officer and Interim Chief Executive Officer of XBiotech, stated:

"We are deeply grateful to Professor Ghiringhelli, the team at Centre Georges-François Leclerc, the French National Cancer Institute, and all the participating patients for advancing this important trial. By uncovering a biomarker-anchored patient population in right-sided disease that derives substantial clinical benefit from vilamakitug, TASKIN provides a focused and validated direction as we advance vilamakitug toward registrational clinical development."

About the TASKIN Trial The TASKIN study (NCT05201352) is an investigator-sponsored clinical trial funded by the French National Cancer Institute (INCa) and sponsored by the Centre Georges-François Leclerc (CGFL) in Dijon, conducted across clinical cancer centers in France. The Phase I portion determined the safety and recommended Phase II dose of vilamakitug with trifluridine/tipiracil and bevacizumab. The double-blind Phase II portion enrolled heavily pre-treated refractory mCRC patients randomized 1:1 to receive standard-of-care trifluridine/tipiracil (± bevacizumab) in combination with either vilamakitug or placebo until disease progression or unacceptable toxicity.

About vilamakitug (Natrunix™, XB2001) A True Human™ therapeutic monoclonal antibody developed solely by XBiotech. Vilamakitug is derived from a human donor that had a natural human immune response against interleukin1alpha (IL-1a). IL-1α is an apex mediator that creates the environment to support growth and emergence of malignant cells. IL-1a stimulates angiogenesis, cellular dysregulation, tissue matrix remodeling, tumor migration, adhesion, and invasion, hallmark physiological features of cancer. Remarkably, vilamakitug has been shown clinically to simultaneously reduce levels of each of VEGF-A, ErbB2/HER2, PDGF, and EGF in cancer patients. Rather than a simple cytotoxic agent that kills all growing tissue, vilamakitug therefore can target multiple aspects of the malignant disease process, facilitating anti-tumor effects while controlling the disease process and reducing disease morbidity. Dramatic reduction in incidence of cancer-related morbidity, reduced hospitalization, reduced duration of hospitalization, reduced symptoms such as diarrhea, fatigue and pain, reduced tumor burden, and longer progression free survival and overall survival have been observed in another study in advanced cancer.

About XBiotech XBiotech is a fully integrated global biosciences company dedicated to pioneering the discovery, development and commercialization of therapeutic antibodies based on its True Human™ discovery platform. XBiotech currently is advancing antibody therapies to redefine the standards of care in oncology, inflammatory conditions and infectious diseases. Headquartered in Austin, Texas, XBiotech also is leading the development of innovative biotech manufacturing technologies designed to more rapidly, cost-effectively and flexibly produce new therapies urgently needed by patients worldwide. For more information, visit www.xbiotech.com.

Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements, including declarations regarding management's beliefs and expectations that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "contemplate," "anticipates," "believes," "estimates," "predicts," "projects," "intend" or "continue" or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the "Risk Factors" section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Prompts

XBiotech Inc. (ticker XBIT), listed in United States.

ETFs Holding XBiotech Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 13,228 $ 24.472K Nov 16, 2026
BSVO 0.00% 59,547 $ 110K Nov 18, 2026